Biogen (BIIB) TD Cowen 46th Annual Health Care Conference summary

Strategic vision and pipeline development

• Focus on rebuilding and expanding the portfolio, with 10 phase 3 programs expected to generate annual readouts through the decade.

• Enhanced productivity and financial discipline have enabled pipeline expansion while reducing R&D spend by 25% over three years.

• Emphasis is shifting to strengthening the early-stage pipeline to support future growth.

Growth outlook and portfolio management

• Recent launches of four growth products have offset declines in the legacy MS portfolio, with continued investment in key assets.

• New product launches and positive trial results, especially in lupus and Alzheimer's, are expected to drive growth into the next decade.

• Revenue is guided to decline by mid-single digits in 2026, with a return to growth anticipated as new assets mature.

Business development and M&A strategy

• M&A is approached cautiously, focusing on assets that fit strategic therapeutic areas and can add near-term cash flow.

• Preference for deals involving assets with phase 3 results or high conviction, avoiding late-decade launches.